<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–51" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–51/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–51/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_51"><akn:num>379j–51</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>§ 379j–51. Definitions
For purposes of this subpart:(1) The term “adjustment factor” applicable to a fiscal year is the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–VA–MD–WV; Not Seasonally Adjusted; All items) for September of the preceding fiscal year divided by such Index for September 2011.

(2) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—(A) one business entity controls, or has the power to control, the other business entity; or

(B) a third party controls, or has power to control, both of the business entities.


(3) The term “biosimilar biological product” means a specific strength of a biological product in final dosage form for which a biosimilar biological product application has been approved.

(4)(A) Subject to subparagraph (B), the term “biosimilar biological product application” means an application for licensure of a biological product under section 262(k) of title 42.

(B) Such term does not include—(i) a supplement to such an application;

(ii) an application filed under section 262(k) of title 42 that cites as the reference product a bovine blood product for topical application licensed before September 1, 1992, or a large volume parenteral drug product approved before such date;

(iii) an application filed under section 262(k) of title 42 with respect to—(I) whole blood or a blood component for transfusion;

(II) an in vitro diagnostic biological product; or

(III) a biological product for further manufacturing use only; or


(iv) an application for licensure under section 262(k) of title 42 that is submitted by a State or Federal Government entity for a product that is not distributed commercially.



(5) The term “biosimilar biological product development meeting” means any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study</akn:p></akn:content><akn:subsection eId="subsec_379j_51_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1) The term “adjustment factor” applicable to a fiscal year is the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–VA–MD–WV; Not Seasonally Adjusted; All items) for September of the preceding fiscal year divided by such Index for September 2011.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3) The term “biosimilar biological product” means a specific strength of a biological product in final dosage form for which a biosimilar biological product application has been approved.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_4"><akn:num>(4)</akn:num><akn:content><akn:p>(4)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_5"><akn:num>(5)</akn:num><akn:content><akn:p>(5) The term “biosimilar biological product development meeting” means any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study intended to support a biosimilar biological product application.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_6"><akn:num>(6)</akn:num><akn:content><akn:p>(6) The term “biosimilar biological product development program” means the program under this subpart for expediting the process for the review of submissions in connection with biosimilar biological product development.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_7"><akn:num>(7)</akn:num><akn:content><akn:p>(7)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_8"><akn:num>(8)</akn:num><akn:content><akn:p>(8) The term “biosimilar initial advisory meeting”—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_9"><akn:num>(9)</akn:num><akn:content><akn:p>(9) The term “costs of resources allocated for the process for the review of biosimilar biological product applications” means the expenses in connection with the process for the review of biosimilar biological product applications for—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_51_10"><akn:num>(10)</akn:num><akn:content><akn:p>(10) The term “final dosage form” means, with respect to a biosimilar biological product, a finished dosage form which is approved for administration to a patient without substantial further manufacturing (such as lyophilized products before reconstitution).</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>